Stroma Biosciences is delighted to announce that it has made the #21toWatch Companies longlist.
The highly respected annual #21toWatch campaign and awards programme showcases the people, companies and ‘things’ that are setting the standards of innovation and entrepreneurship across the Eastern region.
We are proud to have been included in the #21toWatch longlist alongside a host of innovative companies.
Stroma Biosciences, Ltd, a Cambridge based oncology company today announced the appointment of Dr John Beadle as Executive Chairman. Dr Beadle, who previously held the role of CEO at PsiOxus Therapeutics, joins the Stroma Board at a critical time for growth of the...
We have been accepted as a Milner Therapeutics Institute Frameshift company providing us with access to state-of-the art of office and lab space in the Cambridge Biomedical Campus (more information found: https://www.milner.cam.ac.uk/ and...
We are delighted to have raised seed funding investment from Start Codon. The funding will support the development of our research platform and generation of data for our novel targets. Start Codon link: Startcodon.co
